Last reviewed 2026-04-22 · How we verify

BEACOPP escalated q3 weeks

European Organisation for Research and Treatment of Cancer - EORTC · Phase 3 active Small molecule

BEACOPP escalated q3 weeks is a Polychemotherapy regimen Small molecule drug developed by European Organisation for Research and Treatment of Cancer - EORTC. It is currently in Phase 3 development for Hodgkin lymphoma, advanced stages (Phase 3 evaluation).

BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BEACOPP escalated q3 weeks
Sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Drug class	Polychemotherapy regimen
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

BEACOPP escalated is an intensive polychemotherapy combination used primarily in Hodgkin lymphoma. The regimen delivers higher doses of cytotoxic agents compared to standard BEACOPP, targeting malignant lymphocytes through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and mitotic disruption. The escalated dosing is administered every 3 weeks with hematopoietic stem cell support in some protocols.

Approved indications

Hodgkin lymphoma, advanced stages (Phase 3 evaluation)

Common side effects

Myelosuppression (neutropenia, thrombocytopenia)
Infection
Nausea and vomiting
Mucositis
Alopecia
Cardiotoxicity
Pulmonary toxicity

Key clinical trials

Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BEACOPP escalated q3 weeks CI brief — competitive landscape report
BEACOPP escalated q3 weeks updates RSS · CI watch RSS
European Organisation for Research and Treatment of Cancer - EORTC portfolio CI

Frequently asked questions about BEACOPP escalated q3 weeks

What is BEACOPP escalated q3 weeks?

BEACOPP escalated q3 weeks is a Polychemotherapy regimen drug developed by European Organisation for Research and Treatment of Cancer - EORTC, indicated for Hodgkin lymphoma, advanced stages (Phase 3 evaluation).

How does BEACOPP escalated q3 weeks work?

What is BEACOPP escalated q3 weeks used for?

BEACOPP escalated q3 weeks is indicated for Hodgkin lymphoma, advanced stages (Phase 3 evaluation).

Who makes BEACOPP escalated q3 weeks?

BEACOPP escalated q3 weeks is developed by European Organisation for Research and Treatment of Cancer - EORTC (see full European Organisation for Research and Treatment of Cancer - EORTC pipeline at /company/european-organisation-for-research-and-treatment-of-cancer-eortc).

What drug class is BEACOPP escalated q3 weeks in?

BEACOPP escalated q3 weeks belongs to the Polychemotherapy regimen class. See all Polychemotherapy regimen drugs at /class/polychemotherapy-regimen.

What development phase is BEACOPP escalated q3 weeks in?

BEACOPP escalated q3 weeks is in Phase 3.

What are the side effects of BEACOPP escalated q3 weeks?

Common side effects of BEACOPP escalated q3 weeks include Myelosuppression (neutropenia, thrombocytopenia), Infection, Nausea and vomiting, Mucositis, Alopecia, Cardiotoxicity.

Drug class: All Polychemotherapy regimen drugs
Manufacturer: European Organisation for Research and Treatment of Cancer - EORTC — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Hodgkin lymphoma, advanced stages (Phase 3 evaluation)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing